The GLP-1 cash market moved more in the last twelve months than most drug markets move in a decade. Compounded copies are gone, both manufacturers now run direct-to-patient cash programs under $450 a month, and Medicare started covering obesity treatment for the first time. If you are paying cash for a GLP-1 or for insulin in 2026, here is the current map — and the traps printed in the fine print.
Brand-name GLP-1 cash prices, manufacturer-direct (USD per month, August 2026)
The GLP-1 board, August 2026
| Channel | Price | The fine print |
|---|---|---|
| Zepbound single-dose vials, LillyDirect Self Pay | $299 (2.5mg) / $399 (5mg) / $449 (7.5–15mg) | Vials, not pens: you draw and inject with provided syringes. Lower pricing on higher doses requires refilling within 45 days — miss the window and the price can reset |
| Wegovy, NovoCare Pharmacy and partners | ~$349/month standard; $199/month introductory on the two lowest doses | Intro rates are time-limited by definition. Novo extended cash pricing through retail and telehealth partners, so the price travels beyond NovoCare itself |
| Wegovy oral tablets | From ~$149–$299/month depending on dose | The $149 tier covered the lowest doses with promotional windows that expire and reset — the 4mg intro rate was scheduled to end August 31, 2026. Check the current NovoCare page the week you buy |
| Medicare GLP-1 Bridge (from July 1, 2026) | $50 copay per 30-day supply | Zepbound KwikPen only — not the cheap vials. Eligibility: Part D beneficiaries with BMI 35+, or 27+ with qualifying clinical criteria. Runs through 2027 as a demonstration |
| Compounded tirzepatide/semaglutide | Effectively unavailable | FDA declared the shortages resolved and compounding enforcement windows closed in early 2025. Anything still sold as “compounded GLP-1” in 2026 deserves hard scrutiny |
The traps, spelled out
- The refill-window trap: LillyDirect's dose-tier pricing is conditional on 45-day refills. Skipping a month — the most natural thing in the world when money is tight — can cost you the discounted tier.
- The intro-rate trap: $199 Wegovy and $149 tablets are new-patient and low-dose promotional tiers. Budget on the standard rate, treat the intro as a bonus, and screenshot the terms the day you enroll.
- The titration trap: everyone starts at the cheap dose. Maintenance doses are the expensive tiers — price your year at the dose you will end on, not the one you start on.
- The pen-vs-vial trap: Medicare's $50 Bridge copay applies to the KwikPen, not the vials; cash payers get the vial pricing. Same molecule, different containers, different programs.
Insulin: the $35 floor is real, with holes
Insulin is the better story. Medicare Part D caps insulin at $35/month by law. For everyone else, all three major manufacturers run cash programs at the same number: Lilly's Insulin Value Program, Novo Nordisk's MyInsulinRx, and Sanofi's Insulins Valyou — each capping a monthly supply around $35 for cash payers, uninsured included.
- The trap: the $35 programs require enrollment or a downloaded savings card — walking into a pharmacy without one can still produce a $300 retail price for the identical vial. Five minutes on the manufacturer's site first.
- The formulation catch: programs cover each maker's listed products; a niche formulation or a mismatched brand can fall outside the card. Check your exact insulin against the program list.
Where this fits the bigger self-pay picture
Chronic medications are the one category where the US cash market has genuinely improved — manufacturer-direct pricing did what a decade of policy fights could not. Procedures are a different story: surgery pricing remains the canyon it always was, which is what the rest of our US self-pay coverage and the benchmark tables at surgerycost.co exist to map. And a note on travel: GLP-1s are not a medical-tourism play — buying months of a refrigerated injectable abroad creates supply, customs, and cold-chain problems that erase any savings. Buy your meds through the US programs above; save the passport for the procedures.
Final word: this market has repriced itself multiple times since late 2025 and will keep doing it. Every number above was verified in late August 2026 against manufacturer program pages and reporting — treat them as the current snapshot, and re-verify on the manufacturer's own site the week you enroll.
Meds are solvable at home. Procedures are the real fight.
The GLP-1 and insulin programs above are the honest best answers, no middleman needed - use them. Where we earn our keep is the five-figure procedure your deductible was never going to touch: send us the quote and we will show you the real comparison. Operated in person from Medellín via Colombia Medical.
WhatsApp Andy about a procedure quoteEmail AndyFrequently asked questions
What is the cheapest way to get Zepbound without insurance in 2026?
LillyDirect's Self Pay program sells single-dose vials at $299 (2.5mg), $399 (5mg), and $449 (7.5-15mg) per month as of August 2026 - the lowest brand-name tirzepatide cash prices available. The discounted higher-dose tiers require refilling within 45 days, so lapses can cost you the price.
How much is Wegovy without insurance in 2026?
Roughly $349 per month at the standard cash rate through NovoCare Pharmacy and partner pharmacies, with a $199 introductory rate on the two lowest doses and oral tablets from about $149 to $299 depending on dose and current promotional windows. Verify the live price on NovoCare the week you enroll - these tiers have changed repeatedly.
Does Medicare cover Zepbound or Wegovy in 2026?
Partially, and newly. The Medicare GLP-1 Bridge demonstration, effective July 1, 2026, gives eligible Part D beneficiaries (BMI 35+, or 27+ with qualifying criteria) the Zepbound KwikPen for a $50 copay per 30-day supply. The cheap single-dose vials are not part of the program.
How do uninsured patients get $35 insulin?
Enroll in the manufacturer's cash program first - Lilly Insulin Value Program, Novo Nordisk MyInsulinRx, or Sanofi Insulins Valyou - each of which caps a monthly supply around $35 for cash payers. Without the enrollment or savings card, the same vial can ring up at $300 retail. Medicare Part D separately caps insulin at $35 by law.
Sources: Eli Lilly / LillyDirect Self Pay program pricing and terms (December 2025 price reduction, 45-day refill conditions); Novo Nordisk NovoCare Pharmacy pricing and partner expansion; CMS Medicare GLP-1 Bridge demonstration (effective July 1, 2026); FDA compounding enforcement-discretion resolution (2024–2025); manufacturer insulin cash programs; reporting by CNBC and Fierce Pharma; figures verified August 2026. Informational only — not medical, legal, insurance, or financial advice. Prices shown are typical 2026 ranges, not quotes; confirm every figure in writing before paying.